Cargando…
Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19
BACKGROUND: Hydroxychloroquine (HC) ± azithromycin (AZ) is widely used for Covid-19. The Qatar Prospective RCT of Expediting Coronavirus Tapering (Q-PROTECT) aimed to assess virologic cure rates of HC±AZ in cases of low-acuity Covid-19. METHODS: Q-PROTECT employed a prospective, placebo-controlled d...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678437/ https://www.ncbi.nlm.nih.gov/pubmed/33251500 http://dx.doi.org/10.1016/j.eclinm.2020.100645 |
_version_ | 1783612154964869120 |
---|---|
author | Omrani, Ali S. Pathan, Sameer A. Thomas, Sarah A. Harris, Tim R.E. Coyle, Peter V. Thomas, Caroline E. Qureshi, Isma Bhutta, Zain A. Mawlawi, Naema Al Kahlout, Reham Al Elmalik, Ashraf Azad, Aftab M. Daghfal, Joanne Mustafa, Mulham Jeremijenko, Andrew Soub, Hussam Al Khattab, Mohammed Abu Maslamani, Muna Al Thomas, Stephen H. |
author_facet | Omrani, Ali S. Pathan, Sameer A. Thomas, Sarah A. Harris, Tim R.E. Coyle, Peter V. Thomas, Caroline E. Qureshi, Isma Bhutta, Zain A. Mawlawi, Naema Al Kahlout, Reham Al Elmalik, Ashraf Azad, Aftab M. Daghfal, Joanne Mustafa, Mulham Jeremijenko, Andrew Soub, Hussam Al Khattab, Mohammed Abu Maslamani, Muna Al Thomas, Stephen H. |
author_sort | Omrani, Ali S. |
collection | PubMed |
description | BACKGROUND: Hydroxychloroquine (HC) ± azithromycin (AZ) is widely used for Covid-19. The Qatar Prospective RCT of Expediting Coronavirus Tapering (Q-PROTECT) aimed to assess virologic cure rates of HC±AZ in cases of low-acuity Covid-19. METHODS: Q-PROTECT employed a prospective, placebo-controlled design with blinded randomization to three parallel arms: placebo, oral HC (600 mg daily for one week), or oral HC plus oral AZ (500 mg day one, 250 mg daily on days two through five). At enrollment, non-hospitalized participants had mild or no symptoms and were within a day of Covid-19 positivity by polymerase chain reaction (PCR). After six days, intent-to-treat (ITT) analysis of the primary endpoint of virologic cure was assessed using binomial exact 95% confidence intervals (CIs) and χ(2) testing. (ClinicalTrials.gov NCT04349592, trial status closed to new participants.) FINDINGS: The study enrolled 456 participants (152 in each of three groups: HC+AZ, HC, placebo) between 13 April and 1 August 2020. HC+AZ, HC, and placebo groups had 6 (3·9%), 7 (4·6%), and 9 (5·9%) participants go off study medications before completing the medication course (p = 0·716). Day six PCR results were available for all 152 HC+AZ participants, 149/152 (98·0%) HC participants, and 147/152 (96·7%) placebo participants. Day six ITT analysis found no difference (p = 0·821) in groups’ proportions achieving virologic cure: HC+AZ 16/152 (10·5%), HC 19/149 (12·8%), placebo 18/147 (12·2%). Day 14 assessment also showed no association (p = 0·072) between study group and viral cure: HC+AZ 30/149 (20·1%,), HC 42/146 (28·8%), placebo 45/143 (31·5%). There were no serious adverse events. INTERPRETATION: HC±AZ does not facilitate virologic cure in patients with mild or asymptomatic Covid-19. FUNDING: The study was supported by internal institutional funds of the Hamad Medical Corporation (government health service of the State of Qatar). |
format | Online Article Text |
id | pubmed-7678437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-76784372020-11-23 Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 Omrani, Ali S. Pathan, Sameer A. Thomas, Sarah A. Harris, Tim R.E. Coyle, Peter V. Thomas, Caroline E. Qureshi, Isma Bhutta, Zain A. Mawlawi, Naema Al Kahlout, Reham Al Elmalik, Ashraf Azad, Aftab M. Daghfal, Joanne Mustafa, Mulham Jeremijenko, Andrew Soub, Hussam Al Khattab, Mohammed Abu Maslamani, Muna Al Thomas, Stephen H. EClinicalMedicine Research paper BACKGROUND: Hydroxychloroquine (HC) ± azithromycin (AZ) is widely used for Covid-19. The Qatar Prospective RCT of Expediting Coronavirus Tapering (Q-PROTECT) aimed to assess virologic cure rates of HC±AZ in cases of low-acuity Covid-19. METHODS: Q-PROTECT employed a prospective, placebo-controlled design with blinded randomization to three parallel arms: placebo, oral HC (600 mg daily for one week), or oral HC plus oral AZ (500 mg day one, 250 mg daily on days two through five). At enrollment, non-hospitalized participants had mild or no symptoms and were within a day of Covid-19 positivity by polymerase chain reaction (PCR). After six days, intent-to-treat (ITT) analysis of the primary endpoint of virologic cure was assessed using binomial exact 95% confidence intervals (CIs) and χ(2) testing. (ClinicalTrials.gov NCT04349592, trial status closed to new participants.) FINDINGS: The study enrolled 456 participants (152 in each of three groups: HC+AZ, HC, placebo) between 13 April and 1 August 2020. HC+AZ, HC, and placebo groups had 6 (3·9%), 7 (4·6%), and 9 (5·9%) participants go off study medications before completing the medication course (p = 0·716). Day six PCR results were available for all 152 HC+AZ participants, 149/152 (98·0%) HC participants, and 147/152 (96·7%) placebo participants. Day six ITT analysis found no difference (p = 0·821) in groups’ proportions achieving virologic cure: HC+AZ 16/152 (10·5%), HC 19/149 (12·8%), placebo 18/147 (12·2%). Day 14 assessment also showed no association (p = 0·072) between study group and viral cure: HC+AZ 30/149 (20·1%,), HC 42/146 (28·8%), placebo 45/143 (31·5%). There were no serious adverse events. INTERPRETATION: HC±AZ does not facilitate virologic cure in patients with mild or asymptomatic Covid-19. FUNDING: The study was supported by internal institutional funds of the Hamad Medical Corporation (government health service of the State of Qatar). Elsevier 2020-11-20 /pmc/articles/PMC7678437/ /pubmed/33251500 http://dx.doi.org/10.1016/j.eclinm.2020.100645 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research paper Omrani, Ali S. Pathan, Sameer A. Thomas, Sarah A. Harris, Tim R.E. Coyle, Peter V. Thomas, Caroline E. Qureshi, Isma Bhutta, Zain A. Mawlawi, Naema Al Kahlout, Reham Al Elmalik, Ashraf Azad, Aftab M. Daghfal, Joanne Mustafa, Mulham Jeremijenko, Andrew Soub, Hussam Al Khattab, Mohammed Abu Maslamani, Muna Al Thomas, Stephen H. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 |
title | Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 |
title_full | Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 |
title_fullStr | Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 |
title_full_unstemmed | Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 |
title_short | Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 |
title_sort | randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe covid-19 |
topic | Research paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678437/ https://www.ncbi.nlm.nih.gov/pubmed/33251500 http://dx.doi.org/10.1016/j.eclinm.2020.100645 |
work_keys_str_mv | AT omranialis randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT pathansameera randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT thomassaraha randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT harristimre randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT coylepeterv randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT thomascarolinee randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT qureshiisma randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT bhuttazaina randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT mawlawinaemaal randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT kahloutrehamal randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT elmalikashraf randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT azadaftabm randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT daghfaljoanne randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT mustafamulham randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT jeremijenkoandrew randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT soubhussamal randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT khattabmohammedabu randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT maslamanimunaal randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 AT thomasstephenh randomizeddoubleblindedplacebocontrolledtrialofhydroxychloroquinewithorwithoutazithromycinforvirologiccureofnonseverecovid19 |